Cogent Biosciences, Inc.
As of Oct 22, 2026, Cogent Biosciences is in Stage 4, the downtrend phase, now in week 4 (since Sep 30, 2026). It closed at $31.31, 26.9% below its 52-week high and below its 200-day average, which is falling.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is COGT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
COGT among Biotechnology49th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …49 | COGT | Stage 4 · wk 4 | 94 | −0.3% |
Cogent Biosciences: quick answers
What stage is Cogent Biosciences in?
As of Oct 22, 2026, Cogent Biosciences (COGT) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 30, 2026 and is in week 4. What the four stages mean
Is Cogent Biosciences in an uptrend?
No. Cogent Biosciences is in a Stage 4 downtrend. It trades 12.6% below its 200-day average, which is falling.
How far is Cogent Biosciences from its 52-week high?
Cogent Biosciences closed at $31.31 on Oct 22, 2026, 26.9% below its 52-week high of $42.84. Its 52-week low is $14.13.
How has Cogent Biosciences performed over the past year?
As of Oct 22, 2026, Cogent Biosciences is up 97.4% over the past year and down 9.9% so far in 2026.
Which sector and industry is Cogent Biosciences in?
Cogent Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.